You are here: Home News & Press
Document Actions

News & Press

Up one level

Site News

Astellas Pharma US Inc. Pays $7.3 Million to Resolve False Claims Act Allegations Relating to Marketing of Drug Mycamine

The National Association of Medicaid Fraud Control Units announced on July 11, 2014 that 43 states and the District of Columbia have joined with other states and the federal government to settle allegations that Astellas Pharma US Inc. (Astellas) caused false claims to be submitted to federal and state health care programs in connection with its marketing and promotion of the drug Mycamine for pediatric use. Mycamine is a sterile, lyophilized antifungal agent. Astellas Pharma US Inc., located in Northbrook, Ill., manufactures and sells pharmaceutical drugs, including Mycamine.

Read More…

Mallinckrodt Agrees to Pay United States and States 3,500,000 Million Dollars to Resolve False Claim Kickback Case

The National Association of Medicaid Fraud Control Units (NAMFCU) announced on July 18, 2013 that 8 states, as part of a national settlement against Mallinckrodt, has resolved allegations that Mallinckrodt violated the Federal False Claims Act, and various state false claims acts, by providing kickbacks to doctors to effectuate prescription sales of Tofranil-PM, Restoril, and Magnacet.

Read More…

ISTA PHARMACEUTICALS, INC. PAYS $15 MILLION IN SETTLEMENT OF OFF-LABEL MARKETING CLAIMS

NAMFCU announced on July 17, 2013 that the states and the federal government reached an agreement with ISTA Pharmaceuticals, Inc. (“ISTA”) to settle allegations that ISTA marketed its ophthalmic drug Xibrom® for uses that were not approved by the United States Food and Drug Administration (FDA), and paid inducements to doctors to write Xibrom® prescriptions between January 2006 and March 2011.

Read More…

RANBAXY PAYS $500 MILLION TO RESOLVE ADULTERATED DRUGS CLAIMS

The National Association of Medicaid Fraud Control Units announced on May 10, 2013 that the states and the federal government joined in a $500 million dollar settlement to resolve civil and criminal allegations that Ranbaxy, a generic pharmaceutical manufacturer based in Gurgaon, India, introduced adulterated drugs into interstate commerce.

Read More…

Par Pharmaceuticals Agrees to Pay $22.5 Million

The National Association of Medicaid Fraud Control Units announced on March 5, 2013 that the states and the federal government and reached agreement with Par Pharmaceutical Companies, Inc.

Read More…

Healthpoint, LTD

The National Association of Medicaid Fraud Control Units announced on February 21, 2013 that 46 states and the District of Columbia have reached a settlement with Texas-based pharmaceutical manufacturer Healthpoint, Ltd. and its general partner, DFB Pharmaceuticals, to resolve allegations that Healthpoint caused false claims to be submitted to the Medicaid program for an unapproved drug, Xenaderm.

Read More…

VICTORY PHARMA, INC. PAID $12 MILLION IN SETTLEMENT

The National Association of Medicaid Fraud Control Units announced on February 11, 2013 that the states and the federal government to reach agreement with Victory Pharma, Inc. (“VPI”) to settle civil and criminal allegations that VPI paid inducements to physicians for writing prescriptions for the drugs Naprelan, Xodol, Fexmid and Dolgic from January 1, 2007 to December 31, 2009.

Read More…

MERCK TO PAY MORE THAN $915 MILLION TO SETTLE VIOXX CLAIMS WITH STATES AND FEDERAL GOVERNMENT

The National Association of Medicaid Fraud Control Units announced on November 22, 2011 that 42 states and the federal government and reached agreement with Merck Sharp & Dohme Corp. (Merck) to settle civil and criminal allegations that Merck marketed its drug Vioxx for uses not approved by the United States Food and Drug Administration (FDA), misrepresented the cardiovascular safety issues relating to the drug and otherwise made false and misleading representations about Vioxx.

Read More…

ABBOTT LABORATORIES TO PAY $1.5 BILLION HEALTHCARE FRAUD SETTLEMENT

The National Association of Medicaid Fraud Control Units announced on May 4, 2012 that 45 states, the District of Columbia and the federal government reached agreement with Abbott Laboratories to settle civil and criminal allegations that Abbott Laboratories illegally marketed Depakote.

Read More…

NAMFCU ANNOUNCED SETTLEMENT WITH MAXIM HEALTH SERVICES INC.

The National Association of Medicaid Fraud Control Units announced on September 12 that 41 states and the federal government have reached a settlement with Maxim Healthcare Services, Inc. Maxim, a home health agency based in Baltimore, Maryland, provides in-home nursing and home health aide services to people with disabilities in forty-one states.

Read More…

PHARMACEUTICAL COMPANY ALLERGAN TO PAY $600 MILLION FOR OFF LABEL MARKETING OF BOTOX

On September 1, 2010 the National Association of Medicaid Fraud Control Units announced that the states and the federal government reached an agreement in principle with pharmaceutical manufacturer, Allergan, Inc., and Allergan USA, Inc. to settle allegations of improper off-label marketing of the drug Botox.

Read More…

GLAXOSMITHKLINE TO PAY $750 MILLION DOLLARS TO SETTLE ALLEGATIONS OF SELLING ADULTERATED DRUGS

The National Association of Medicaid Fraud Control Units announced on October 26, 2010, that the states and the federal government have reached an agreement in principle with the pharmaceutical manufacturer GlaxoSmithKline (GSK) to settle allegations that the company introduced adulterated drugs into interstate commerce.

Read More…

NOVARTIS TO PAY $422.5 MILLION TO SETTLE CLAIMS OF OFF-LABEL DRUG MARKETING AND KICKBACKS

The National Association of Medicaid Fraud Control Units announced on September 30, 2010 that the states and the federal government to reach an agreement in principle with Novartis Pharmaceuticals Corporation (Novartis) to settle allegations it improperly promoted Trileptal and engaged in unlawful kickback schemes to induce physicians to prescribe Trileptal, Diovan, Zelnorm, Sandostatin, Exforge and Tekturna.

Read More…